Navigation Links
Risk of Breast Cancer Relapse Can Linger
Date:8/12/2008

Study shows recurrence after five-year mark, but numbers aren't as high as some might suspect, study says

TUESDAY, Aug. 12 (HealthDay News) -- The risk of relapse can linger for some breast cancer survivors even after completing five years of what doctors call systemic therapy, a new study found.

But, as gloomy as that news sounds, there is a relative bright spot: the risk may not be as dire as many women fear.

"I would like to think these numbers are smaller than women think they are," the study's lead author, Dr. Abenaa Brewster, a medical oncologist at the University of Texas M.D. Anderson Cancer Center in Houston, said.

Most women, she added, "remain terrified they are going to relapse. I think the message for women is, the risk may not be as large as they think."

Brewster's team evaluated 2,838 breast cancer patients whose disease ranged from stage I to III. All had been treated with some form of adjuvant systemic therapy between 1985 and 2001 and had remained disease-free for five years, which is traditionally considered a landmark in cancer survival.

The women had a variety of treatments -- surgery, chemotherapy, radiotherapy or endocrine therapy. Endocrine therapy involves tamoxifen, aromatase inhibitors and a combination of the drugs and is usually given for five years.

About 10 years after the diagnosis, 89 percent of the women remained recurrence-free. And about 80 percent remained recurrence-free 15 years after the diagnosis.

In all, 216 patients developed a recurrence, Brewster said. She found that the risk or recurrence varied by stage and tumor type. Those women with stage I disease had a 7 percent chance of relapse; stage II, 11 percent; and stage III, 13 percent.

Besides the stage of cancer at diagnosis, hormone receptor status affected risk, the study found. "Women who had ER-positive cancer were more likely to have late recurrences than those with ER-negative," Brewster said. This finding held true for premenopausal and postmenopausal women. While 34 ER-negative women had a relapse, 149 ER-positive did.

"Estrogen receptor status is a tumor marker we look at," Brewster said. "We know that those who have ER-positive tumors [have] cancers that are responsive to the effects of estrogen."

While women in the study were taking a variety of hormone therapies, none took five years of aromatase inhibitors, which are now the standard of care for postmenopausal women but weren't when the study began in 1985, Brewster said.

The study findings were published online Aug. 12 in the Journal of the National Cancer Institute.

Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, said the study findings leave some unanswered questions, such as the best course of action at the five-year mark. But it offers some interesting information, he added.

"The major message is that even though women may have gone through five years of hormonal therapy, they are still at risk of relapse," he said. Another important finding, he added, is that those women with ER-positive tumors seem to be at higher risk than those with ER-negative tumors.

"Basically the jury is out on the potential value of additional treatment strategies once the five years is completed," Lichtenfeld said. "Based on this study, we need to be open to question whether other treatment programs may be appropriate in some of these women after the five-year period is completed."

More information

To learn more about hormone therapy for breast cancer, visit the American Cancer Society.



SOURCES: Abenaa Brewster, M.D., assistant professor of medicine and medical oncologist, University of Texas M.D. Anderson Cancer Center in Houston; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Aug. 12, 2008, Journal of the National Cancer Institute


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Risk assessment plays key role in long-term treatment of breast cancer
2. MedexSupply Announces the Release of the ADC Limited Edition Pink Ribbon Stethoscope, With Proceeds Being Donated to Breast Cancer Research
3. Breast-Feeding: The Stress Buster That Lasts for Years
4. Beyond PTEN: Alternate genes linked to breast, thyroid and kidney cancer predisposition
5. Adjunct Breast Imaging Market to Increase by Almost 28% per Year Through 2013
6. Susan G. Komen for the Cure(R) Comments on Christina Applegates Breast Cancer Diagnosis
7. Breast CT Scans Could Be Comfortable Alternative to Mammograms
8. Mary Ann Liebert, Inc. Provides Complimentary Online Access to Breastfeeding Medicine for the Month of August
9. Minorities less likely to know about breast cancer treatment options
10. 2 different breast cancer screening strategies are equally effective
11. 2 Breast Cancer Screening Strategies Prove Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... ... Pennsylvania, is pleased to offer in-home and online newborn sleep consultations . ... has on the body,” says company owner Courtney Zentz, a pediatric sleep professional, ...
(Date:9/22/2017)... ... 22, 2017 , ... TopConsumerReviews.com recently awarded their highest five-star ... promote pancreatic health and regulate blood sugar levels . , Preventing diabetes ... negative side effects, and with the changes in today’s healthcare industry, not everyone ...
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of ... Home” is the creation of published author, John Allred, a passionate leader of ministry ... International, who has traveled and ministered on four continents. , “It is my hope ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... 38-Year-Old Plastic ... Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill ... 40 Under 40 is an annual award that was started in 2003 ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology: